Neurocrine Biosciences Inc. (NASDAQ:NBIX) traded up 2.9% during trading on Monday . The stock traded as high as $52.85 and last traded at $51.70, with a volume of 411,547 shares changing hands. The stock had previously closed at $50.23.

Several equities research analysts recently commented on the company. Jefferies Group reissued a “buy” rating on shares of Neurocrine Biosciences in a research note on Sunday, May 8th. Robert W. Baird reissued a “buy” rating on shares of Neurocrine Biosciences in a research note on Sunday, May 8th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a research report on Tuesday, April 12th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $96.00 target price on shares of Neurocrine Biosciences in a research report on Monday, May 16th. Finally, TheStreet cut Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, July 14th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $63.90.

The firm’s market capitalization is $4.37 billion. The firm’s 50 day moving average is $46.95 and its 200-day moving average is $43.47.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.07. During the same period in the prior year, the business earned ($0.01) EPS. The business had revenue of $15 million for the quarter, compared to analyst estimates of $15.43 million. The company’s revenue for the quarter was down 24.1% compared to the same quarter last year. Equities analysts anticipate that Neurocrine Biosciences Inc. will post ($1.94) EPS for the current fiscal year.

In related news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $46.72, for a total value of $700,800.00. Following the sale, the director now owns 15,464 shares of the company’s stock, valued at approximately $722,478.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Christopher Flint Obrien sold 25,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $45.00, for a total value of $1,125,000.00. Following the completion of the sale, the insider now directly owns 80,044 shares in the company, valued at approximately $3,601,980. The disclosure for this sale can be found here.

A number of large investors have recently made changes to their positions in NBIX. California Public Employees Retirement System raised its stake in shares of Neurocrine Biosciences by 16.1% in the fourth quarter. California Public Employees Retirement System now owns 184,200 shares of the company’s stock worth $10,420,000 after buying an additional 25,600 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Neurocrine Biosciences by 7.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 134,303 shares of the company’s stock worth $7,597,000 after buying an additional 9,793 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Neurocrine Biosciences by 0.3% in the fourth quarter. Principal Financial Group Inc. now owns 160,233 shares of the company’s stock worth $9,065,000 after buying an additional 449 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Neurocrine Biosciences by 6.6% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,221,642 shares of the company’s stock worth $69,108,000 after buying an additional 75,797 shares in the last quarter. Finally, Russell Frank Co raised its stake in shares of Neurocrine Biosciences by 10.7% in the fourth quarter. Russell Frank Co now owns 53,358 shares of the company’s stock worth $3,014,000 after buying an additional 5,148 shares in the last quarter.

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.